Antibe Therapeutics, Inc. (ATBPF) Starts Presentation at Marcum MicroCap Conference

Antibe Therapeutics (OTC: ATBPF) develops medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. For more information, visit the company’s website at www.antibethera.com